Size, Share & Industry Analysis, By Type (Cell Therapy Drugs, Gene Therapy Drugs, Edited cells versus vectors), By Application (Oncology, Rare Genetic Disorders, Cardiovascular Diseases and Others), By End User (Specialized Treatment Centers, Hospital, Clinic), By Technology Platform (Viral Vectors, Genome Editing, Non-Viral Vectors), and Global Forecast, 2026-2034
Explore the report section by section.
The global Cell and Gene Therapy (CGT) Pharmaceuticals Market was valued at USD 18.15 billion in 2025 and is estimated at USD 21.60 billion in 2026. Revenue is projected to reach USD 86.60 billion by 2034, equivalent to a 19.0% CAGR during 2026–2034.
Cell and gene therapy pharmaceuticals include licensed autologous or allogeneic cell products, genetically modified immune-cell medicines, in-vivo gene-delivery products and ex-vivo gene-edited cell treatments. The market measures external manufacturer revenue from products and qualifying development or clinical-supply activities; intercompany transfers and royalties attributable to already-counted finished-product sales are excluded. Hospital infusion and transplant support costs are not included as pharmaceutical sales. These boundaries keep oncology CAR-T medicines distinct from unrelated biologic cancer drugs.
Licensed oncology cell therapies generate recurring quarterly product sales across multiple CAR-T franchises. Gilead reported USD 1.8 billion of 2025 cell-therapy sales from Yescarta and Tecartus, while Legend Biotech reported USD 1.9 billion in worldwide CARVYKTI net trade sales. Novartis reported USD 1.232 billion in Zolgensma group revenue, showing that inherited-disease gene therapy also contributes materially. These company disclosures support the existence of a multibillion-dollar commercial market, but each covers specific franchises rather than the entire global cell and gene therapy universe.
Casgevy access remains limited by myeloablative conditioning, specialist manufacturing and prolonged follow-up requirements. The FDA requires lifetime monitoring for secondary malignancies after certain CD19- or BCMA-directed CAR-T products. For sickle cell disease, the US CMS CGT Access Model links payment arrangements to outcomes, with 33 states plus the District of Columbia and Puerto Rico joining in 2025. England added the Autolus product Aucatzyl in November 2025 for adults whose B-cell acute lymphoblastic leukemia returned or resisted previous treatment, expanding another specialist treatment pathway.
Gene editing is moving into younger patient groups: in July 2026 the FDA broadened Casgevy eligibility to qualifying patients from age two with serious inherited hemoglobin disorders. The European Medicines Agency also lists Casgevy and CARVYKTI among authorized advanced therapies. Each expansion increases the number of eligible patients but depends on certified centers, cell collection and specialized monitoring. Forecast revenue therefore reflects treatment capacity and reimbursement as well as the number of approvals.
Source: FDA approved cell and gene therapies; Gilead FY2025; Legend Biotech FY2025; CMS CGT Access Model.
Revenue includes approved cell and gene therapy pharmaceutical products and qualifying in-scope development receipts, with each transaction counted once. Patient hospital stays, conditioning chemotherapy, unrelated biologics and broad contract-manufacturing revenue are excluded.
| Report Attribute | Coverage |
|---|---|
| Base Year | 2025 |
| Estimated Year | 2026 |
| Forecast Period | 2026–2034 |
| Market Measurement | Revenue, USD million/billion |
| By Type | Cell Therapy Drugs; Gene Therapy Drugs |
| By Application | Oncology; Rare Genetic Disorders; Cardiovascular Diseases; Others |
| By End User | Hospital; Clinic; Specialized Treatment Centers |
| By Technology Platform | Viral Vectors; Non-Viral Vectors; Genome Editing |
| By Region | North America; Europe; Asia-Pacific; Latin America; Middle East & Africa |
| Selected Countries | United States; Canada; United Kingdom; Germany; Australia; Japan; Brazil; Saudi Arabia |
| Key Market Players | Novartis; Gilead Sciences; Bristol Myers Squibb; Johnson & Johnson; Legend Biotech; Vertex Pharmaceuticals; CRISPR Therapeutics; Ferring Pharmaceuticals; Iovance Biotherapeutics; Autolus Therapeutics; CSL Behring; Orchard Therapeutics |
Cell Therapy Drugs denotes medicines administered as living therapeutic cells, including autologous CAR-T, tumor-infiltrating lymphocytes and ex-vivo edited hematopoietic stem cells such as Casgevy. Gene Therapy Drugs covers in-vivo vector-delivered products and other directly administered gene-modifying medicines. Products are assigned by administered dosage form, so a gene-edited cell product is not counted again under direct gene therapy.
Oncology and Rare Genetic Disorders are distinct therapeutic indications; Cardiovascular Diseases covers the disease-attributable activity of eligible cell or gene treatments, and Others covers remaining conditions. End User is classified by the administering institution: certified or designated cell-therapy centers take precedence over ordinary hospitals, while Clinic refers to outpatient facilities outside those centers. Technology Platform is assigned by the primary engineering method: Genome Editing takes priority over Viral Vectors where both are used, and Non-Viral Vectors captures remaining delivery methods.
Gilead reported USD 1.8 billion in 2025 sales from Yescarta and Tecartus, even as competition reduced that franchise from the prior year. Legend Biotech reported CARVYKTI worldwide trade sales of USD 1.9 billion, reflecting wider use in multiple myeloma. These figures show that approved immune-cell therapies have moved beyond one-time launch revenue, while also demonstrating competitive displacement between products. Manufacturers must expand treatment-center capacity and manage vein-to-vein production time to translate eligible patients into actual infusions and repeatable quarterly revenue.
Novartis reported USD 1.232 billion in 2025 Zolgensma group sales, while Casgevy addresses eligible patients with sickle cell disease and transfusion-dependent beta thalassemia. Such therapies are administered infrequently per patient and require specialized work-up, so patient starts rather than chronic refills determine annual sales. CMS introduced outcomes-based agreements for sickle cell gene therapy, and 33 US states joined its model during 2025. A payer can limit financial risk through performance-linked rebates, but the hospital still needs capacity for conditioning and post-treatment care.
The FDA required boxed warnings for T-cell malignancies after specified CD19- and BCMA-directed autologous CAR-T immunotherapies in April 2024. The agency recommends lifelong monitoring for secondary malignancies, creating long-duration follow-up requirements after a single infusion. Hospitals must maintain registries, patient education and adverse-event reporting systems alongside cytokine-release syndrome management. These obligations raise delivery complexity and may constrain center throughput, but credible surveillance also supports continued use of therapies with demonstrated benefits in heavily pretreated cancers.
Autologous therapies require collection of each patient’s cells, genetic modification, release testing and coordinated delivery back to the treatment center. CARVYKTI reached 294 sites worldwide according to Legend Biotech’s March 2026 update, showing how network expansion supports sales. Ex-vivo edited stem-cell products also require myeloablative conditioning and extended inpatient care, limiting the number of centers that can offer treatment safely. Manufacturers investing in capacity can reduce delays, but reimbursement approval and clinical suitability remain necessary before production slots translate into revenue.
Sources: Gilead FY2025; Legend Biotech FY2025; Novartis FY2025; FDA CAR-T safety communication; CMS CGT Access Model.
A July 2026 FDA label extension made Casgevy available to certain children from age two with sickle cell disease or transfusion-dependent beta thalassemia. Casgevy uses CRISPR-edited autologous hematopoietic stem cells rather than an off-the-shelf gene-delivery injection. Earlier treatment may increase the eligible population, but collection, myeloablation and specialist hospitalization remain substantial barriers. The extension also increases the need for long-term pediatric outcome tracking, so clinical centers and manufacturers must align monitoring capacity with access programs.
NHS England announced access to Autolus Aucatzyl in November 2025 for adults whose B-cell acute lymphoblastic leukemia returned or resisted previous treatment. The therapy is manufactured from a patient’s own engineered T cells and delivered at selected specialist centers. Existing CAR-T products already compete in lymphoma and myeloma, so additional approvals increase choice while intensifying scheduling and staffing requirements. Market growth depends on expanding center throughput rather than simply adding products to formularies, particularly where inpatient monitoring capacity is limited.
The European Medicines Agency maintains an advanced therapy medicinal product framework and published a joint warning with national authorities in March 2025 about unregulated advanced therapies. Its authorized portfolio includes Casgevy, CARVYKTI and newer rare-disease treatments. Legitimate commercial products require marketing authorization or an appropriate national pathway; investigational cell infusions marketed outside trials should not be counted as approved medicine sales. Regulatory clarity benefits manufacturers with validated production and pharmacovigilance systems, but also increases documentation and quality-assurance costs for clinical supply.
CMS said its sickle cell CGT Access Model would cover states representing about 84% of Medicaid beneficiaries with the disease after 2025 participation agreements. Outcomes-based contracts link some manufacturer rebates to results, allowing payers to manage uncertainty about long-term benefit. England negotiated access for Casgevy through the NHS, while Australia funded CARVYKTI for eligible multiple myeloma patients in public hospitals in May 2026. These policies widen treated populations without guaranteeing unrestricted use, because each health system applies eligibility and center-capacity requirements.
The Type axis divides administered living-cell medicines from directly delivered gene therapy products. Cell Therapy Drugs include CAR-T, tumor-infiltrating lymphocyte products and gene-edited cell infusions. Gene Therapy Drugs cover in-vivo viral-vector and other directly administered genetic medicines. An ex-vivo edited cell is allocated to the cell category only, even when regulators classify the product as a gene therapy.
Cell Therapy Drugs represented an estimated ~63% of 2025 revenue. Gilead Yescarta and Tecartus, Johnson & Johnson and Legend CARVYKTI, and Bristol Myers Squibb cellular products contribute to a mature oncology sales base. Iovance Amtagvi and Autolus Aucatzyl broaden the commercial cell-therapy set. Manufacturing is patient-specific for many products, so production slots, quality release and treatment-center coordination determine realized sales.
Gene Therapy Drugs include in-vivo products such as Novartis Zolgensma and other gene-delivery medicines for inherited disorders. Zolgensma group sales reached USD 1.232 billion in 2025, showing substantial demand despite rare-disease patient populations. Revenue can be volatile because one-time treatments do not generate chronic refills, and each additional market requires regulatory approval, screening and payer negotiation.
Casgevy is administered as a gene-edited hematopoietic stem-cell product and belongs to Cell Therapy Drugs under the dosage-form rule. Directly administered vectors belong to Gene Therapy Drugs. This assignment prevents the same treatment being counted twice merely because the manufacturing process includes both cells and genetic engineering. Product definitions remain aligned with the FDA approved-therapy register.
Cell therapies are expected to retain value leadership while directly delivered gene medicines expand across rare diseases. Growth in either type remains constrained by eligible patient identification, treatment-center infrastructure and outcome-linked reimbursement.
Therapeutic applications comprise Oncology, Rare Genetic Disorders, Cardiovascular Diseases and Others. Each product is assigned to its principal marketed indication, with secondary approved indications allocated by attributable sales rather than counted again in full. CAR-T oncology is the largest application, while gene editing is expanding treatment options for inherited blood disorders.
Oncology represented an estimated ~62% of 2025 revenue, led by CAR-T medicines for lymphoma, leukemia and multiple myeloma. Gilead, Bristol Myers Squibb and Johnson & Johnson have established commercial products in these indications. The FDA warning on secondary T-cell malignancies adds a lifelong follow-up obligation, while expanded treatment lines can enlarge the eligible population. CAR-T product sales remain dependent on specialist referral networks and validated manufacturing capacity.
Rare Genetic Disorders include sickle cell disease, transfusion-dependent beta thalassemia, spinal muscular atrophy and other inherited conditions treated with approved genetic medicines. The FDA extended Casgevy to younger children in July 2026, and Novartis markets Zolgensma for spinal muscular atrophy. Screening and genetic confirmation define eligible patients, while one-time dosing means demand must be replenished by new diagnoses and broader access.
Cardiovascular Diseases account for a smaller commercial segment because many investigational cell approaches have not reached broad authorization. Others includes licensed treatments outside oncology and inherited disorders, such as selected tissue or bladder cancer gene therapies classified by their actual indications. Development-stage receipts are included only when attributable to the modality and not already embedded in finished-product sales. Research-stage programs lack the marketing authorization required for routine licensed pharmaceutical sales.
Oncology will remain the main near-term revenue driver, but growth in inherited diseases can become more meaningful as reimbursement and newborn or genetic screening improve access. Cardiovascular revenue should not be inflated using conventional regenerative procedures outside approved pharmaceutical boundaries.
End users are assigned by where the medicine is administered: Hospital, Clinic or Specialized Treatment Centers. The specialized-center category has priority for certified CAR-T and stem-cell transplantation programs, even when the center is physically located inside a hospital. General hospitals and outpatient clinics are classified separately to avoid double counting.
Specialized Treatment Centers represented the largest 2025 revenue pool, supported by CAR-T infusion networks and gene-edited stem-cell programs. Legend Biotech reported 294 CARVYKTI sites worldwide in March 2026, illustrating the importance of authorized capacity. These centers coordinate apheresis, conditioning, infusion, toxicity management and long-term follow-up, and often determine the practical number of patients treated in a given quarter.
Hospitals outside certified cell-therapy networks provide selected authorized medicines, diagnostic work-up and supportive care. Complex oncology or inherited-disease patients may be referred onward to a specialized site when product labelling requires designated facilities. Revenue is allocated to the site administering the pharmaceutical, not to every hospital that participates in the referral pathway. This distinction matters because supportive care costs are not CGT drug sales.
Clinics contribute a smaller portion of manufacturer revenue through eligible outpatient products and specialist follow-up. Many autologous CAR-T and gene-edited stem-cell regimens require hospital-level monitoring, so an ordinary clinic cannot substitute for a certified center. Expansion of outpatient pathways depends on product safety profiles, local regulation and reimbursement arrangements. Follow-up visits after CAR-T infusion are not counted as separate pharmaceutical sales in the defined revenue boundary.
Specialized centers should remain the dominant channel for complex living-cell medicines, while simplified products and delivery processes may increase the outpatient contribution. Capacity investment, training and quality oversight will determine how rapidly new centers enter commercial networks.
Technology Platform partitions primary manufacturing and delivery methods into Viral Vectors, Non-Viral Vectors and Genome Editing. To preserve exclusivity, a CRISPR-edited cell therapy is assigned to Genome Editing even if a viral reagent is used elsewhere in manufacturing. Viral Vectors captures the primary viral transduction or in-vivo vector platform for remaining products.
Viral Vectors represented the leading technology share in 2025, reflecting lentiviral CAR-T manufacturing and adeno-associated viral delivery in inherited-disease medicines. Novartis Zolgensma uses an AAV platform, while several commercial CAR-T products use viral transduction. Established production processes support large-batch manufacturing, but viral-vector quality testing and capacity can be costly. The category excludes CRISPR-edited products allocated to Genome Editing.
Genome Editing includes CRISPR-based modification of patient cells, with Casgevy providing a licensed commercial example. The FDA expanded its pediatric label in July 2026, increasing the potential treated population while maintaining demanding collection and conditioning steps. Manufacturing precision, off-target monitoring and long-term clinical follow-up affect uptake. The segment is defined by its primary gene-editing mechanism rather than by the presence of cells in the finished medicine.
Non-Viral Vectors include eligible nonviral delivery and engineering platforms used in marketed products or qualifying development activities. The segment is smaller than viral methods because fewer established commercial therapies rely on these approaches. Developers seek reduced manufacturing complexity and repeat-dosing possibilities, but clinical effectiveness and regulatory approval remain product-specific. Research-stage methods without in-scope revenue do not automatically contribute to the market.
Viral vectors should retain the largest installed commercial base, while genome editing can grow as licensed indications expand. Technology mix depends on demonstrated patient benefit and manufacturability rather than on the number of preclinical platform announcements.
Revenue concentration follows approvals, net selling prices, reimbursement and access to certified manufacturing and treatment centers. North America leads by value; Europe has established ATMP pathways, Asia-Pacific is expanding funded access, and Brazil and Saudi Arabia are developing advanced-therapy oversight.
North America held an estimated ~53% of 2025 revenue, supported by US commercial CAR-T products, high one-time treatment prices and a large network of certified infusion sites. Gilead recorded USD 1.8 billion in cell-therapy sales during 2025, while Legend reported CARVYKTI global sales of USD 1.9 billion. The US FDA lists multiple licensed cell and gene therapy products across oncology and inherited diseases, providing a clear regulatory base for market activity. CMS introduced a new access model for sickle cell gene therapy with outcomes-linked agreements, reflecting the challenge of paying for high-cost, potentially durable treatments. Canada participates in North American demand through authorized products and specialist centers, but its payer negotiations and provincial access differ from US commercial insurance. Regional expansion depends on expanding infusion capacity, genetic screening and reimbursement for conditioning and follow-up, not merely on new product approvals.
CMS announced that 33 states, the District of Columbia and Puerto Rico joined its CGT Access Model in July 2025, representing about 84% of Medicaid beneficiaries with sickle cell disease. The program uses outcomes-based agreements for qualifying gene therapies, linking payment risk to clinical results. The FDA also extended Casgevy to eligible children aged two and older in July 2026, expanding the addressable pediatric population.
Source: CMS.
Europe has a structured regulatory pathway for advanced therapy medicinal products, including genetically modified cells and gene-delivery medicines. The EMA maintains authorized-product records for CARVYKTI and Casgevy and warned in March 2025 against unregulated advanced therapies offered outside legitimate authorization or trials. NHS England negotiated access to Casgevy for eligible sickle cell disease patients and introduced Aucatzyl for certain adults with B-cell acute lymphoblastic leukemia in November 2025. The United Kingdom therefore illustrates how a central health service can translate authorization into funded specialist treatment, although eligibility remains narrow. Germany and other European markets require separate national pricing or reimbursement decisions after authorization, which can stagger launches. Commercial demand is concentrated in accredited centers capable of apheresis, cell handling and toxicity management. European expansion will depend on evidence of durable benefit and the ability of payers to finance one-time therapies.
NHS England announced Aucatzyl access on 25 November 2025 for adult B-cell leukemia patients who had not responded to prior treatment. The therapy is delivered through selected specialist CAR-T centers and was supported by interim funding to accelerate implementation. England had also agreed access to Casgevy for severe sickle cell disease earlier in 2025, showing how national commissioning affects uptake of expensive one-time treatments.
Source: NHS England.
Asia-Pacific combines established advanced-therapy approvals in Japan and Australia with a large potential population requiring specialist infrastructure. Australia announced public-hospital access to CARVYKTI for eligible multiple myeloma patients in May 2026, reducing the direct financial burden for those meeting clinical criteria. Japan has an established regulator and specialist oncology centers, while other countries face uneven reimbursement and local manufacturing capacity. In many markets, the challenge is not the availability of clinical trial information but the ability to arrange cell collection, shipping, release testing and infusion within approved centers. Local manufacturing and technology-transfer programs could reduce transport delays, although every product still requires validated quality controls. Australian government funding also demonstrates that approved CAR-T use can expand without removing the need for qualified hospital teams. Rising demand for inherited-disease treatments depends on screening and timely referral, while CAR-T growth depends on treatment slots and multidisciplinary monitoring rather than broad retail distribution.
On 5 May 2026 the Australian Government announced that eligible patients with multiple myeloma could receive CARVYKTI without direct treatment charges in public hospitals. The announcement identified a treatment cost exceeding AUD 200,000 per patient without government funding. This funding decision creates a concrete route to uptake, but delivery remains limited to clinically eligible patients and hospitals capable of CAR-T administration. Local infusion teams must coordinate monitoring for acute toxicities after treatment.
Source: Australian Government.
Latin America remains a smaller commercial region because one-time advanced therapies require high budgets, qualified centers and sustained follow-up. Brazil has established a regulatory framework for advanced therapy products and has authorized medicines including Kymriah, Yescarta, CARVYKTI, Luxturna and Zolgensma. In January 2025, Anvisa published periodic monitoring reports covering registered advanced therapies, reinforcing post-authorization benefit-risk surveillance. The presence of authorized products does not mean broad population access; health-system procurement, specialist referral and financial arrangements still determine patient starts. Research centers in Brazil are also investigating locally developed CAR-T approaches, but experimental administration must not be described as routine licensed commercial therapy. Elsewhere in the region, access can depend on private insurance and cross-border referral. Commercial growth should follow expansion of qualified centers and clearer payer policies rather than general cancer incidence alone. Brazilian post-registration monitoring also makes continued safety surveillance a condition of sustainable access for several licensed products.
Anvisa published monitoring reports for registered advanced therapy products on 27 January 2025, including CARVYKTI, Kymriah, Luxturna, Yescarta and Zolgensma. The reports review safety and effectiveness evidence collected after approval, providing a framework for ongoing risk assessment. Brazil has also supported experimental domestic CAR-T development, which remains distinct from registered pharmaceutical sales. Procurement and center qualification remain necessary for commercial patient access.
Source: Anvisa.
The Middle East and Africa contribute a smaller share of cell and gene therapy pharmaceutical revenue because treatment requires specialized infrastructure, genetic testing and access to high-cost medicines. Saudi Arabia is developing local CAR-T research capacity alongside regulatory oversight. In August 2025, the Saudi Food and Drug Authority authorized a Phase I study of locally developed CAR-T cells for CD19-positive adult leukemia patients whose disease had recurred or resisted treatment. This was a clinical trial authorization, not a marketing approval or evidence of commercial product sales. The distinction matters because many regional programs remain investigational while imported licensed therapies require separate regulatory and reimbursement decisions. Concentrated specialist hospitals may provide initial access, but broader adoption depends on trained staff, apheresis facilities, quality-controlled manufacturing and long-term monitoring. Regional demand cannot be inferred from the number of announced clinical studies.
On 28 August 2025 the Saudi Food and Drug Authority authorized a Phase I clinical study of locally developed CAR-T cells for CD19-positive adult leukemia patients whose disease had recurred or resisted treatment. The authorization concerns research and does not establish routine commercial availability. Local development could eventually support regional manufacturing expertise, but a product would still need successful trials and marketing authorization before pharmaceutical sales are counted.
Source: Saudi FDA.
Commercial competition spans established oncology manufacturers, rare-disease gene-therapy suppliers and focused cell-therapy developers. Gilead sells Yescarta and Tecartus, while Bristol Myers Squibb markets Breyanzi and Abecma. Johnson & Johnson and Legend Biotech are associated with CARVYKTI, whose 2025 net trade sales reached USD 1.9 billion. Novartis has the Zolgensma franchise and CAR-T experience, and Vertex commercializes Casgevy with CRISPR Therapeutics. These portfolios address different indications and patient populations rather than competing as interchangeable drugs.
Yescarta and Tecartus generated USD 1.8 billion in 2025 sales.
CARVYKTI reached USD 1.9 billion in 2025 global net trade sales.
Zolgensma group recorded USD 1.232 billion in 2025 sales.
Casgevy expanded to eligible children aged two and older in the United States in July 2026.
Ferring Pharmaceuticals markets the gene therapy Adstiladrin for certain bladder cancer patients, while Iovance Biotherapeutics commercializes Amtagvi, a tumor-infiltrating lymphocyte product for melanoma. Autolus markets Aucatzyl for eligible leukemia patients and obtained an NHS England access decision in 2025. CSL Behring participates in in-vivo gene therapy through Hemgenix, and Orchard Therapeutics has rare-disease gene-therapy expertise under Kyowa Kirin. Product-specific regulatory status and commercial activity determine whether each company belongs in the competitive set.
CAR-T manufacturers compete on efficacy, durability, safety and manufacturing turnaround. Gilead reported a 7% decline in 2025 cell-therapy product revenue, while Legend described expansion to 294 CARVYKTI treatment sites by March 2026. Those developments indicate that commercial performance varies across products even when the wider modality is growing. Developers must coordinate with hospitals to manage patient scheduling, apheresis and product release; competition is therefore partly about service reliability rather than only clinical endpoints.
For inherited conditions, companies face different barriers: identifying eligible patients, negotiating one-time prices and arranging conditioning or specialist administration. CMS outcome-based agreements and NHS funding decisions can materially influence sales timing. Emerging genome-editing programs must demonstrate durable benefit and safety before entering commercial forecasts as approved products. The FDA and EMA product registers are essential for distinguishing licensed therapies from investigational assets, and financial disclosures should not be double-counted when a product is co-developed by two companies.
July 2026: Casgevy gained an expanded US indication for qualifying patients from their second birthday with severe inherited blood conditions. The decision broadens potential pediatric treatment while retaining requirements for stem-cell collection, conditioning and long-term follow-up. This extension makes pediatric referral pathways and fertility-preservation counselling more important for eligible families. Source
May 2026: Australia announced publicly funded CARVYKTI treatment for eligible adults with relapsed or refractory multiple myeloma. The decision improves affordability within designated hospitals and may increase treatment starts, although eligibility criteria and specialist capacity still govern actual use. The public-hospital rollout reduces patient payment exposure but requires qualified infusion teams and ongoing toxicity surveillance. Source
March 2026: Legend Biotech reported 2025 CARVYKTI net trade sales of USD 1.9 billion and availability across 294 sites worldwide. The update provides evidence of commercial uptake and wider treatment-center reach for a BCMA-directed CAR-T medicine in multiple myeloma. Wider site coverage can shorten travel distances for eligible patients and support manufacturing scheduling. Source
January 2026: The European Medicines Agency issued marketing authorization for Waskyra, an advanced therapy for eligible patients with Wiskott-Aldrich syndrome. The approval adds a rare-disease option to the European ATMP portfolio, subject to indication-specific specialist assessment and ongoing monitoring. The European pathway also requires product-specific quality documentation and pharmacovigilance. Source
November 2025: NHS England announced access to Aucatzyl for qualifying adult patients whose B-cell acute lymphoblastic leukemia had returned or proved resistant. The medicine is delivered at selected CAR-T centers, highlighting how national reimbursement decisions and specialist site capacity jointly determine commercial access. Autologous collection and manufacturing must be coordinated before infusion dates can be confirmed. Source
August 2025: Saudi regulators permitted first-in-human testing of a locally developed CAR-T approach in adult CD19-positive leukemia. This was permission to investigate a treatment, not a marketing authorization; commercial revenue requires a later approved product. The study may build local technical expertise, but the Phase I authorization does not establish routine treatment availability. Source
Revenue from cell and gene therapy pharmaceuticals is projected to rise from USD 21.60 billion in 2026 to USD 86.60 billion by 2034, consistent with 19.0% compound annual growth.
| Forecast variable | Current commercial signal | Potential effect |
|---|---|---|
| CAR-T competition | Established Yescarta and CARVYKTI sales | Earlier-line use and site expansion drive volume |
| Gene editing | Casgevy pediatric label extension | More eligible patients but complex administration |
| Payer contracts | CMS outcomes-based model | Improves access while sharing durability risk |
| Regulatory oversight | FDA and EMA approved-product registers | Differentiates licensed sales from clinical programs |
Commercial growth through 2034 will depend on treatment starts rather than chronic refill frequency. The 2025 sales disclosed for CARVYKTI, Gilead cell therapies and Zolgensma show that multiple modalities already generate substantial revenue. However, product sales can move in opposite directions as new indications and competitors change prescribing patterns. Capacity planning, referral networks and manufacturing reliability will determine how much of the eligible patient pool can actually be treated.
Cell Therapy Drugs should remain the largest type by value, with oncology the leading indication. New CAR-T products and earlier treatment lines can expand use in lymphoma, leukemia and myeloma, while FDA safety warnings require lifelong monitoring for certain products. Manufacturing time and patient fitness will continue to limit the speed of uptake. Developers that reduce turnaround delays or simplify logistics may gain share even without materially changing list prices.
Gene-edited and vector-based treatments can broaden the rare-disease segment as approvals extend to younger patients and additional conditions. The July 2026 Casgevy expansion demonstrates this pathway, but gene-edited stem-cell administration still requires conditioning and specialist follow-up. NHS access agreements, Australian funding and CMS outcomes-linked payment arrangements show how health systems are addressing high upfront costs. Wider coverage can increase volume, while negotiated prices and performance rebates may temper revenue per patient.
CGT access across regions will vary with national reimbursement decisions and certified treatment-center availability. North America has established commercial networks and high treatment spending; Europe relies on EMA authorization plus country-level reimbursement; Australia has funded selected CAR-T use; Brazil has a post-approval monitoring framework; and Saudi Arabia is developing local clinical research. Regulatory approvals, payer agreements and clinical trials alone cannot guarantee high-volume pharmaceutical sales. The forecast remains sensitive to approved indications, manufacturing slots, patient screening and evidence of durable outcomes.
Coverage follows licensed cell and gene therapy pharmaceuticals and attributable in-scope development activity, with clear boundaries for product and patient administration.
The worldwide market was valued at **USD 18.15 billion in 2025**. It includes qualifying pharmaceutical sales of cell and gene therapies across oncology and inherited diseases. Hospital procedure fees and conventional biologics are excluded, while partner transactions are allocated to avoid counting the same finished product twice.
Global cell and gene therapy pharmaceutical revenue is projected at **USD 86.60 billion by 2034**. Expansion depends on new licensed indications, certified treatment-center capacity and reimbursement for expensive one-time therapies. Clinical trial announcements without marketing authorization do not represent approved-product revenue in the forecast.
The forecast implies a **19.0% CAGR from 2026 to 2034**, with 2026 revenue estimated at USD 21.60 billion. The growth rate reflects the broader commercial uptake of CAR-T and gene therapies rather than a guaranteed annual increase for every manufacturer.
Cell Therapy Drugs represented an estimated **~63% of 2025 revenue**. Commercial CAR-T products such as Yescarta and CARVYKTI contribute to this category, together with other living-cell medicines. Directly administered gene-delivery products are classified separately to avoid double counting.
Oncology accounted for an estimated **~62% of 2025 revenue**. Approved CAR-T products treat selected lymphomas, leukemias and multiple myeloma. Rare Genetic Disorders form another important application, with products such as Zolgensma and Casgevy serving specific inherited conditions.
Yes. The FDA lists licensed CAR-T products including Yescarta, Tecartus, Breyanzi, Abecma and CARVYKTI for defined indications. Approval does not extend to every cancer type or investigational construct. Certain products also carry boxed warnings about secondary T-cell malignancies and require long-term monitoring.
In July 2026 the US regulator widened the Casgevy label to cover certain patients aged two and above with inherited blood disorders. The therapy uses CRISPR-edited autologous stem cells and requires specialized collection, conditioning and monitoring.
North America held an estimated **~53% of 2025 revenue**. US approvals, established CAR-T treatment networks and substantial manufacturer sales support that position. CMS is testing outcomes-based agreements for sickle cell gene therapies, which may widen Medicaid access while managing payment risk.
Reimbursement depends on the product, patient eligibility and national or private payer rules. CMS introduced outcome-linked contracts for sickle cell gene therapy, while NHS England and Australia have funded selected advanced therapies through specialist centers. These decisions do not remove the need for clinical screening and hospital capacity.
Commercial participants include Gilead, Bristol Myers Squibb, Johnson & Johnson, Legend Biotech, Novartis, Vertex, Ferring, Iovance and Autolus. Their licensed products serve different cancers and inherited disorders, with indication-specific labels and monitoring requirements. FDA and EMA registers provide product-level authorization information; company pipeline announcements should not be treated as sales of licensed medicines.
Display logos only where use is approved. A logo does not imply a public endorsement.
The data provided by 24LifeScience was clear, well-organized, and useful for internal strategy planning. It helped us understand the competitive landscape more effectively.
We used one of their market overview reports for early-stage feasibility work. It gave us a helpful snapshot of current trends and key players in our therapeutic area.
I appreciated the team’s responsiveness and willingness to adjust the scope based on our feedback. The final report was aligned with our expectations and timelines.
Their custom report on clinical trial trends was a helpful reference as we explored new indications.
As someone working on early product planning, I found their therapeutic-area briefs useful and easy to apply in our internal discussions.
We needed dependable data and a clearly presented market structure. The research gave us a practical starting point for our assessment.
Publish named testimonials only when the individual and organization have approved disclosure.
Review the report scope, forecast timeframe, methodology, and cited evidence before deciding whether the full study fits your requirement.
Coverage, segmentation, geography, and market boundaries are stated within the report.
Readers can review the published sources and evidence referenced in this market overview.
Base, estimated, and forecast years are shown to place the market outlook in context.
Each overview displays its report identifier and latest update date.
A structured view of market size, forecast outlook, segmentation, regional dynamics, competitive activity, and the research framework behind this study.
Review the market estimate, growth outlook, forecast direction, and key factors influencing future demand.
Understand the report’s defined segments, demand drivers, applications, end users, and market opportunities.
Assess regional performance, selected country context, and factors shaping adoption across major markets.
Explore company profiles, market positioning, and selected developments relevant to the market landscape.
Review key demand drivers, challenges, emerging opportunities, technology shifts, and factors influencing market direction.
Understand the report scope, market boundaries, research approach, and evidence referenced in the published market overview.